Literature DB >> 31933734

Atractylodesin III maintains mitochondrial function and inhibits caspase-3 activity to reverse apoptosis of cardiomyocytes in AMI rats.

Mingying Cao1, Cheng Yu2, Zhuhua Yao1, Xuemei Gao1, Shuxing Wu1.   

Abstract

The aim of the present study was to analyze the effects of Atractylodesin III (codonopsis pilosula) extract that maintains mitochondrial function, up-regulates Bcl-2, inhibits Caspase-3 activity, and ultimately leads to cardiomyocyte apoptosis in a rat model of acute myocardial infarction (AMI). 30 male Sprague-Dawley rats aged 6 months, weighed 150-200 g were randomly divided into sham operation group (SOG), model group (MG) and intervention group (IG). The IG was intragastrically administered with atractylodesin III (30 mg/kg/d) for 7 days. The model group was treated with (30 mg/kg/d) of sterile saline. After 4.5 h, the heart samples from each group were taken, the myocardial infarct size was detected by 2, 3, 5-triphenyltetrazolium chloride (TTC) staining.After ematoxylin & Eosin (HE) staining apoptosis indices were determined by Terminal deoxynucleotidyl transferase TdT-mediated dUTP Nick-End Labeling (TUNEL) method. Apoptosis-related genes and protein including Bcl-2, Bax, and Caspase-3 expression were determined by quantitative real time polymerase chain reaction (qRT-PCR) and western blot respectively. The infarct size and apoptotic index of the MG were significantly higher than SOG. However, infarct size and apoptotic index were reduced in IGcompared to MG (P < 0.05). The levels of Bax and Caspase-3 in the MG were significantly higher, while Bcl-2 and Bcl-2/Bax were lower than those in the SOG. The IG has lower levels of Bax and Caspase-3, higher levels of Bcl-2 and Bcl-2/Bax (P < 0.05) compared to MG. Atractylodesin III decreased apoptosis of myocardial cells in AMI, up-regulated Bcl-2 expression, and inhibited Bax and Caspase-3 activity. IJCEP
Copyright © 2019.

Entities:  

Keywords:  AMI; Atractylenolide III; apoptosis; caspase-3; mitochondrial function

Year:  2019        PMID: 31933734

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  6 in total

1.  Atractylenolide III alleviates the apoptosis through inhibition of autophagy by the mTOR-dependent pathway in alveolar macrophages of human silicosis.

Authors:  Shi Chen; Kun Tang; Peiwu Hu; Shiyi Tan; Shang Yang; Chang Yang; Gang Chen; Yixiao Luo; Hui Zou
Journal:  Mol Cell Biochem       Date:  2020-10-19       Impact factor: 3.396

2.  Jianpiyifei II Granules Suppress Apoptosis of Bronchial Epithelial Cells in Chronic Obstructive Pulmonary Disease via Inhibition of the Reactive Oxygen Species-Endoplasmic Reticulum Stress-Ca2+ Signaling Pathway.

Authors:  Long Fan; Leng Li; Xuhua Yu; Ziyao Liang; Tiantian Cai; Yuanbin Chen; Yinji Xu; Tao Hu; Lei Wu; Lin Lin
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

3.  Atractylenolide I alleviates ischemia/reperfusion injury by preserving mitochondrial function and inhibiting caspase-3 activity.

Authors:  Caiqin Sun; Xuesong Zhang; Fei Yu; Chen Liu; Fangbin Hu; Li Liu; Jing Chen; Jue Wang
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

4.  The Obesity Amelioration Effect in High-Fat-Diet Fed Mice of a Homogeneous Polysaccharide from Codonopsis pilosula.

Authors:  Qi Su; Jiangyan Huo; Yibin Wang; Yang Zhou; Dan Luo; Jinjun Hou; Zijia Zhang; Huali Long; Xianchun Zhong; Cen Xie; Min Lei; Yameng Liu; Wanying Wu
Journal:  Molecules       Date:  2022-08-22       Impact factor: 4.927

5.  Atractylenolide III Attenuates Apoptosis in H9c2 Cells by Inhibiting Endoplasmic Reticulum Stress through the GRP78/PERK/CHOP Signaling Pathway.

Authors:  Meng-Yu Zuo; Tong-Juan Tang; Xiang Wang; Jin-Fan Gu; Liang Wang; Jian Chen; Juan Yao; Xiang-Yang Li; Peng Zhou; Jin-Ling Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-14       Impact factor: 2.650

6.  LuQi Formula Regulates NLRP3 Inflammasome to Relieve Myocardial-Infarction-Induced Cardiac Remodeling in Mice.

Authors:  Xiaoqing Zhang; Dandan Zhao; Jiling Feng; Xiaoli Yang; Zhenzhen Lan; Tao Yang; Xiaoni Kong; Huiyan Qu; Hua Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-28       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.